Sector rotation into healthcare and biotech adds tailwinds to AMRN’s valuation. The amrn stock forecast this quarter incorporates broader ETF inflows, which could buoy price levels past recent highs. Taking into account the latest results, the four analysts covering Amarin provided consensus estimates of US$213.6m revenue in 2024, which would reflect a concerning 30% decline over the past 12 months. Losses are forecast to balloon 26% to US$0.18 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$226.1m and losses of US$0.15 per share in 2024. While this year's revenue estimates dropped there was also a regrettable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock. Since the trial results, Amarin stock has remained highly volatile. Yes, it’s clear Amarin has a viable commercial product on their hands now, but how many doctors will start prescribing it? Revenue diversification away from the single-drug model is on AMRN’s strategic agenda. Success here could re-rate valuation multiples and shift the amrn stock forecast curve notably higher over the next 12 months.